Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging studyRalf Reilmann, Hope Heller, Robin Schubert et al.|The Lancet Neurology|2018Cited by 108
Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington DiseaseAndrew McGarry, Michael R. Hayden, Peggy Auinger et al.|Journal of Huntington s Disease|2020Cited by 22
Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington’s DiseaseAndrew McGarry, Michael R. Hayden, Karl Kieburtz et al.|Journal of Huntington s Disease|2017Cited by 18
Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results from the Phase II, Double-blind, Placebo-controlled, Dose-Ranging Study, Pride-HD (P2.005)Karl Kieburtz, Michael R. Hayden, G. Bernhard Landwehrmeyer et al.|Neurology|2017Cited by 10